Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
71,6 CHF | -0,69 % | +0,28 % | +40,67 % |
26/04 | Cosmo Pharmaceuticals N.V. anuncia cambios ejecutivos en la próxima Junta General Anual del 24 de mayo de 2024 | CI |
25/04 | Cosmo Pharmaceuticals nombra nuevo consejero delegado y presidente | MT |
Resumen de negocios
Número de empleados: 319
Ventas por actividad
CHF en millones | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
Own Products
52,0
%
| 43 | 60,6 % | 53 | 52,0 % | +25,05 % |
Licence Fees, Up-front Fees and Milestones
23,8
%
| 6 | 8,5 % | 24 | 23,8 % | +310,51 % |
Generic Products, Specialty Drugs and Related Services
12,9
%
| 14 | 19,4 % | 13 | 12,9 % | -3,41 % |
Royalties
9,7
%
| 6 | 8,6 % | 10 | 9,7 % | +63,17 % |
Other
1,6
%
| 2 | 2,9 % | 2 | 1,6 % | -17,40 % |
Ventas por región
CHF en millones | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
Italy
100,0
%
| 70 | 100,0 % | 102 | 100,0 % | +45,72 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 61 | 01/01/06 | |
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 01/06/16 |
Chief Tech/Sci/R&D Officer | 54 | - | |
Luigi Longo
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/06/05 |
Davide Malavasi
CTO | Chief Tech/Sci/R&D Officer | 51 | 01/09/11 |
Marco Lecchi
COO | Chief Operating Officer | 60 | 01/01/01 |
Hazel Winchester
IRC | Investor Relations Contact | 53 | 10/01/22 |
Nhan Ngo Dinh
PRN | Corporate Officer/Principal | 45 | - |
Biagio Viganò
HRO | Human Resources Officer | 50 | - |
Diana Harbort
PRN | Corporate Officer/Principal | 57 | 01/01/22 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
David W Maris
BRD | Director/Board Member | 57 | 28/05/21 |
Founder | 69 | 01/01/97 | |
Director/Board Member | 64 | 01/01/06 | |
Director/Board Member | 69 | 01/04/12 | |
Director/Board Member | 65 | 01/03/16 | |
Chief Executive Officer | 61 | 01/01/06 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 17 543 522 | 7 805 026 ( 44,49 %) | 1 490 681 ( 8,497 %) | 44,49 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
1 283 390 | 7.32% | 101 593 999 $ |
Información de la empresa
Cosmo Pharmaceuticals NV
Riverside II Sir John Rogerson's Quay
2, Dublin
+353 1 817 0370
http://www.cosmopharma.comEmpresas del grupo
Nombre | Categoría y sector |
---|---|
Pharmaceuticals: Major
| |
Cosmo Technologies Ltd.
Cosmo Technologies Ltd. Pharmaceuticals: MajorHealth Technology Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish pharmaceutical company that manufactures and distributes pharmaceutical products. The private company is based in Dublin, Ireland. Cosmo Technologies was acquired by Salix Pharmaceuticals Ltd. from Cosmo Pharmaceuticals SA. |
Pharmaceuticals: Major
|
Granell Strategic Investment Fund Ltd.
|
Investment Managers
|
Ventas por actividad
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+40,67 % | 1256,54 M | |
+25,83 % | 661 mil M | |
+27,00 % | 566 mil M | |
-6,76 % | 352 mil M | |
+20,34 % | 332 mil M | |
+3,00 % | 283 mil M | |
+13,09 % | 231 mil M | |
+5,46 % | 200 mil M | |
-9,61 % | 195 mil M | |
-6,26 % | 145 mil M |
- Bolsa de valores
- Acciones
- Acción COPN
- Empresa Cosmo Pharmaceuticals N.V.